Literature DB >> 16007533

BK virus: opportunity makes a pathogen.

Hans H Hirsch1.   

Abstract

More than 70% of the general population worldwide has serological evidence of exposure to Polyomavirus hominis type 1, better known as BK virus (BKV). BKV infection typically occurs during childhood, without specific symptoms, followed by a state of nonreplicative infection in various tissues, with the urogenital tract as the principal site. Asymptomatic reactivation and low-level replication with viruria is observed in 5% of healthy individuals. Persistent high-level BKV replication is the hallmark of polyomavirus-associated nephropathy in renal transplantation and of hemorrhagic cystitis in bone marrow transplantation. Since these manifestations are rare in other types of immunocompromised patients, the presence of specific cofactors is postulated. The role of BKV in autoimmune disease and cancer is a controversial topic and is difficult to determine, because the pathology no longer depends on BKV replication. This article discusses current views of pathogenesis, diagnosis, and treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16007533     DOI: 10.1086/431488

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  79 in total

Review 1.  Sex differences in transplantation.

Authors:  Jeremiah D Momper; Michael L Misel; Dianne B McKay
Journal:  Transplant Rev (Orlando)       Date:  2017-02-20       Impact factor: 3.943

2.  A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients.

Authors:  Benjamin J D Weist; Patrizia Wehler; Linda El Ahmad; Michael Schmueck-Henneresse; Jason M Millward; Mikalai Nienen; Avidan U Neumann; Petra Reinke; Nina Babel
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

Review 3.  Polyomavirus-associated nephropathy.

Authors:  Cristina Costa; Rossana Cavallo
Journal:  World J Transplant       Date:  2012-12-24

4.  Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T Cell-depleted peripheral blood and cord blood stem cell transplantations.

Authors:  Yeon Joo Lee; Junting Zheng; Yovanna Kolitsopoulos; Dick Chung; Isabelle Amigues; Tammy Son; Kathleen Choo; Jeff Hester; Sergio A Giralt; Ilya G Glezerman; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-23       Impact factor: 5.742

5.  A short tale of blood, kidney and brain: BK virus encephalitis in an allogeneic stem cell transplant recipient.

Authors:  C Bourlon; S Alamoudi; D Kumar; A Viswabandya; S Thyagu; F V Michelis; D D-H Kim; J H Lipton; H A Messner; U Deotare
Journal:  Bone Marrow Transplant       Date:  2017-02-20       Impact factor: 5.483

6.  Modeling Immune Response to BK Virus Infection and Donor Kidney in Renal Transplant Recipients.

Authors:  H T Banks; Shuhua Hu; Kathryn Link; Eric S Rosenberg; Sheila Mitsuma; Lauren Rosario
Journal:  Inverse Probl Sci Eng       Date:  2015-03-13       Impact factor: 1.950

7.  Restriction of human polyomavirus BK virus DNA replication in murine cells and extracts.

Authors:  Cathal Mahon; Bo Liang; Irina Tikhanovich; Johanna R Abend; Michael J Imperiale; Heinz P Nasheuer; William R Folk
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 8.  The role of polyomaviruses in human disease.

Authors:  Mengxi Jiang; Johanna R Abend; Silas F Johnson; Michael J Imperiale
Journal:  Virology       Date:  2008-11-07       Impact factor: 3.616

9.  Hydronephrosis Resulting from Bilateral Ureteral Stenosis: A Late Complication of Polyoma BK Virus Cystitis?

Authors:  N Basara; F-M Rasche; T Schwalenberg; C Wickenhauser; M Maier; J Ivovic; D Niederwieser; T H Lindner
Journal:  J Transplant       Date:  2010-09-27

10.  Gallic acid-based small-molecule inhibitors of JC and BK polyomaviral infection.

Authors:  Bethany A O'Hara; Chamila Rupasinghe; Achani Yatawara; Gabriel Gaidos; Dale F Mierke; Walter J Atwood
Journal:  Virus Res       Date:  2014-06-21       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.